Denton Andrew B, Tsaparas Yotis
Department of Otolaryngology, University of British Columbia, Vancouver, British Columbia, Canada.
Otolaryngol Head Neck Surg. 2007 Apr;136(4):563-7. doi: 10.1016/j.otohns.2006.11.049.
To evaluate the use of Perlane, an injectable form of hyaluronic acid, for the correction of HIV-associated facial lipoatrophy.
A prospective, observational study in a consecutive series of 18 HIV-positive males with facial lipoatrophy injected with Perlane. Fourteen patients were available for final analysis.
Mean follow-up time was 12 months. Based on photographic analysis, there was a significant early improvement (P = 0.0035). This difference remained significant after 12 months (P = 0.04666); no significant difference in grade was shown between 1 and 12 months (P = 0.3693). Office assessments of improvement showed an early marked improvement in 85.8% of patients, and 78.6% of subjects demonstrated at least moderate improvement at 12 months.
CONCLUSION/SIGNIFICANCE: Patient satisfaction was high, with only minor side effects and no late complications. Our findings support Perlane to be a feasible option for the provisional correction of mild to moderate facial lipoatrophy.
评估透明质酸注射剂Perlane用于矫正与艾滋病相关的面部脂肪萎缩的效果。
对连续18例面部脂肪萎缩的HIV阳性男性患者注射Perlane进行前瞻性观察研究。14例患者可供最终分析。
平均随访时间为12个月。根据照片分析，早期有显著改善（P = 0.0035）。12个月后这种差异仍然显著（P = 0.04666）；1个月和12个月之间等级无显著差异（P = 0.3693）。门诊改善评估显示，85.8%的患者早期有明显改善，78.6%的受试者在12个月时至少有中度改善。
结论/意义：患者满意度高，只有轻微副作用且无晚期并发症。我们的研究结果支持Perlane是临时矫正轻至中度面部脂肪萎缩的可行选择。
